

CRST – Excellence in proving your concept

Clinical Research Services Turku CRST – partnering with Turku PET Centre

- ✓ University-based CRO that conducts clinical, preclinical and bioanalytical studies for the pharmaceutical industry and for other customers
- ✓ Experienced in demanding phase 0-2 clinical trials and proof-of-concept studies
- ✓ Employing Positron Emission Tomography (PET) to assess efficacy and pharmacokinetics

CRST

Scientific and regulatory consultancy
Medical writing, regulatory submissions
Subject recruitment
Investigators, study nurses and clinical wards with 24/7 safety monitoring
In-house bioanalytical laboratory for analysis of PK and biomarker samples
Clinical study monitoring
Project management

Turku PET Centre

State-of-the-art PET imaging facilities
MRI, CT and ultrasound imaging
PET radiochemistry expertise with cyclotrons and GMP radiopharmaceutical laboratories
Extensive track record in pharma trials from preclinical to clinical

www.turkupetcentre.fi

CRST – Excellence in proving your concept

Focus on PET and oncology – clinical proof-of-concept studies with cancer drugs

- ✓ PET-MRI/CT imaging provides unique benefits as a quantitative surrogate marker for treatment effect
- ✓ Treatment effect can be detected early in clinical studies with only small number of patients

PET tracer	Mechanism	Target applications in clinical trials
¹¹ C-acetate	Lipid synthesis	Recurrent prostate cancer, liver tumours
¹⁸ F-fluoride	Osteoclast activity and bone perfusion	Bone metastases
⁶⁸ Ga-DOTATOC, ⁶⁸ Ga-DOTANOC	Somatostatin receptor ligands	Neuroendocrine tumours
¹⁸ F-fluorodopa (FDOPA)	Transport and storage of biogenic amines	Neuroendocrine tumours, recurrent brain tumours
¹¹ C-methionine	Transport of amino acids	Recurrent brain tumours
¹⁸ F-fluoroborono-phenylalanine (FBPA)	Transport of amino acids	Recurrent brain tumours and head and neck cancers
¹¹ C-methomidate	Inhibition of 11 β -hydroxylase	Tumours of the adrenal cortex
¹⁸ F-EF5	Hypoxia	Various solid tumours
¹⁸ F-deoxyglucose (FDG)	Tissue glucose uptake and consumption	General marker of solid tumours and lymphomas
¹⁵ O-H ₂ O	Tissue blood perfusion	Solid tumours (non-specific)

Clinical Research Services Turku CRST, Itäinen Pitkäkatu 4 B, 3rd floor, FI-20520 Turku, Finland

Phone: +358 2 333 7635 | Fax: +358 2 251 0046 | E-mail: crst@utu.fi | Internet: www.crst.fi